Tu1515: CLIMB: A PROSPECTIVE, BLINDED, MULTICENTER U.S. BASED STUDY EVALUATING A MULTI-ANALYTE BLOOD-BASED TEST FOR DETECTING HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH LIVER CIRRHOSIS
David J. Taggart(ID Genomics (United States)), Mindie H. Nguyen(Stanford Medicine), Ju Dong Yang(Mayo Clinic), Nadege Gunn, Allison J. Sorg, Maxime A. Gallant, Itai Pinkoviezky, Bradley Freilich(Kansas City Research Institute), Roniel Cabrera, Richard A. Van Etten(University of California, Irvine), Curt C. Roberts, Dmitri Slinkov, Wei Li(Jilin University), Jianfeng Xu(NorthShore University HealthSystem), John H. Smith(Digestive & Liver Disease Specialists), Emmanuel C. Gorospe, Shivani Mahajan, Bal Raj Bhandari(Ironwood Pharmaceuticals (United States)), Ziad Younes(American College of Veterinary Surgeons), Humberto Aguilar, Abdullah Mubarak
Cited by 1
Related Papers
Tyrosine Kinases as Targets for Cancer Therapy
|New England Journal of Medicine|2005|1.4k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
|New England Journal of Medicine|2014|907
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
|Hepatology|2015|689
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
|New England Journal of Medicine|2017|565